Pluristem Therapeutics Inc. (PSTI) Sees Significant Growth in Short Interest

Pluristem Therapeutics Inc. (NASDAQ:PSTI) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 827,945 shares, a growth of 59.3% from the April 15th total of 519,722 shares. Based on an average daily volume of 719,714 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.6% of the shares of the company are sold short.

In other news, CEO Yaky Yanay bought 71,429 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were bought at an average price of $0.70 per share, with a total value of $50,000.30. Following the completion of the transaction, the chief executive officer now owns 4,253,045 shares of the company’s stock, valued at $2,977,131.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.70% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the stock. ETF Managers Group LLC grew its position in Pluristem Therapeutics by 49.6% during the fourth quarter. ETF Managers Group LLC now owns 250,848 shares of the biotechnology company’s stock worth $192,000 after buying an additional 83,207 shares in the last quarter. Virtu Financial LLC grew its position in Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after buying an additional 61,858 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new stake in Pluristem Therapeutics during the first quarter worth approximately $900,000. Renaissance Technologies LLC grew its position in Pluristem Therapeutics by 5.8% during the third quarter. Renaissance Technologies LLC now owns 1,331,100 shares of the biotechnology company’s stock worth $1,730,000 after buying an additional 72,600 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in Pluristem Therapeutics by 38.7% during the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock worth $40,000 after buying an additional 14,087 shares in the last quarter. 5.93% of the stock is currently owned by institutional investors and hedge funds.



Several equities analysts have recently commented on the company. Zacks Investment Research downgraded Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Maxim Group reaffirmed a “buy” rating and issued a $3.00 target price on shares of Pluristem Therapeutics in a research report on Wednesday, April 24th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $3.19.

Pluristem Therapeutics stock opened at $0.67 on Monday. Pluristem Therapeutics has a 12 month low of $0.50 and a 12 month high of $1.52. The company has a market capitalization of $97.36 million, a PE ratio of -2.68 and a beta of 1.13.

TRADEMARK VIOLATION WARNING: “Pluristem Therapeutics Inc. (PSTI) Sees Significant Growth in Short Interest” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/05/27/pluristem-therapeutics-inc-psti-sees-significant-growth-in-short-interest.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Read More: How to read a candlestick chart

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.